门冬氨酸钾镁联合氯化钾与硫酸镁联合氯化钾治疗心力衰竭的比较

目的：比较门冬氨酸钾镁联合氯化钾（门冬联用组）与硫酸镁联合氯化钾（硫酸镁联用组）在治疗充血性心力衰竭（ＣＨＦ）中的疗效。方法：将２７０例ＣＨＦ病人分为２组。门冬联用组９９例在常规治疗基础上加用门冬氨酸钾镁４０～６０ｍＬ联合１０％氯化钾１０ｍＬ治疗；硫酸镁联用组１７１例加用２５％硫酸镁５～１０ｍＬ联合１０％氯化钾１０～１５ｍＬ治疗；２组药物均分别溶于５％葡萄糖注射液５００ｍＬ中静脉滴注，ｑｄ，疗程均为１０ｄ。结果：门冬联用组对难治性ＣＨＦ的疗效优于硫酸镁联用组（Ｐ＜０．０５）；前者抗心律失常疗效优于后者，且无明显不良反应，而后者因Ｍｇ２＋相对高浓度的扩血管作用，在ＣＨＦ血压偏低状态下其应用受到限制。结论：治疗ＣＨＦ门冬联用氯化钾优于硫酸镁联用氯化钾。

Potassium magnesium aspartate plus potassium chloride vs magnesium sulfate plus potassium chloride in treatment of heart failure

AIM: To compare the clinical efficacies between potassium magnesium aspartate plus potassium chloride and magnesium sulfate plus potassium chloride in the treatment of congestive heart failure (CHF). METHODS: Two hundred and seventy patients with CHF were divided into 2 groups, on the basis of conventional therapy. The first group (M 68, F 31; age 58 a±s 8 a) was treated with addition of potassium magnesium aspartate 40_60 mL plus 10% potassium chloride 10 mL; and second group (M 126, F 45; age 53 a±8 a) was treated with the addition of 25% magnesium sulfate 5_10 mL plus 10% potassium chloride 10_15 mL, both in 5% glucose injection 500 mL, iv, drip, qd×10 d. RESULTS: The first group were better than the second group in the treatment of refractory heart failure (P<0.05) and cardiac arrhythmias. Adverse reactions were not found in the first group. In the second group, when the patients were in the state of low_blood pressure, the medicines were confined because of the higher concentration of magnesium. CONCLUSION: Potassium magnesium aspartate plus potassium chloride were better than magnesium sulfate plus potassium chloride in the treatment of CHF.